Article Versions Notes

Ihlow J, Monjé N, Hoffmann I, Bischoff P, Sinn BV, Schmitt WD, Kunze CA, Darb-Esfahani S, Kulbe H, Braicu EI, et al. Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancers. 2022; 14(19):4620. https://doi.org/10.3390/cancers14194620

Ihlow, Jana, Nanna Monjé, Inga Hoffmann, Philip Bischoff, Bruno Valentin Sinn, Wolfgang Daniel Schmitt, Catarina Alisa Kunze, Sylvia Darb-Esfahani, Hagen Kulbe, Elena Ioana Braicu, and et al. 2022. "Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer" Cancers 14, no. 19: 4620. https://doi.org/10.3390/cancers14194620

Ihlow, J., Monjé, N., Hoffmann, I., Bischoff, P., Sinn, B. V., Schmitt, W. D., Kunze, C. A., Darb-Esfahani, S., Kulbe, H., Braicu, E. I., Sehouli, J., Denkert, C., Horst, D., & Taube, E. T. (2022). Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancers, 14(19), 4620. https://doi.org/10.3390/cancers14194620